Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | Molecular Imaging | April 20, 2016

Why Politics (and Money) Will Define the Next Generation of Scanners

Why Politics (and Money) Will Define the Next Generation of Scanners

Photo courtesy of Pixabay

It’s been a long time since radiology focused just on the detection of disease. And it will never see those days again.

Since the serendipitous discovery of X-rays’ ability to reveal what is otherwise hidden, radiological devices have evolved with improved sensitivity and specificity, and the need to meet increasingly “practical considerations,” euphemisms that allude to money.

The U.S. Food and Drug Administration (FDA) rises above such considerations, looking just at efficacy when reviewing medical devices for marketing in the U.S. Similarly the Centers for Medicare and Medicaid Services (CMS) base coverage decisions on the proven clinical value of medical devices. But cost is creeping into, some might say even storming the gates of, medical practice.

Legislators are looking for ways to rein in costs associated with Medicare and Obamacare. Consequently the realization is taking hold that medicine must become more efficient and effective. Soon.

In this new reality, ease-of-use plays a central role, streamlining workflow in ways that cut costs and shrink the time from door to treatment. If future research demonstrates improved patient outcome, increased efficiency will have achieved a healthcare hat trick.

Baby Steps

While it is easy to see individual steps in this journey, it is more difficult to see where they are leading. In radiology, clearly the direction is toward a new generation of scanners that continue the journey beyond the traditional focus of finding disease to one that addresses the continuum of patient care.

Of course, diagnosis will continue to be a big part of radiology’s mission. But therapy assessment and planning will take on added weight. We are already headed in this direction, as seen in steps taken over the last 15 years with the hybridization of positron emission tomography (PET) and computed tomography (CT), single photon emission computed tomography (SPECT) and CT, and most recently PET and magnetic resonance (MR). In each, efficiency in patient management, particularly patient prognosis and therapy assessment, has been the overriding consideration. And molecular imaging is not alone. 

This directional change is evident in all branches of imaging — the flat panel digitalization of radiography, fluoroscopy, mammography, angiography and cardiac cath; the extension of CT into functional analysis via spectral imaging; the automation of ultrasound and MR — notable in ultrasound for efforts designed to deliver results that are less operator dependent and, therefore, more reproducible; in MR for the standardization of protocols depending on patient habitus and the suspected or proven disease being investigated.

Driving this change are forces that have come not from engineering labs but rather the fiscal recesses of this country’s political system, and their roots extend much deeper than Uncle Sam’s pocket book. Simply put, the U.S. is running out of fiscal options to stimulate its economy. An aging workforce threatens its ability to grow the economy enough to offset its ballooning debt. At the same time the cost of healthcare, particularly in Medicare, threatens to apply added heft to this debt load.

Conflicting Forces Align

On the one hand, the longevity of America’s workforce must be extended. On the other, healthcare costs must be controlled. The confluence of these two seemingly contrary demands — one based on generating revenue, the other on absorbing it — is creating the political will to take action. As has happened before, the political will to implement change has defined imaging technology. But what’s coming will dwarf what has been.

In the past, the political power behind women’s health led to widespread screening with mammography and the adoption of digital technologies spurred by specially crafted reimbursement rates. Might a surge of interest in men’s health, spurred by the need to extend the utility of the aging American workforce, have a similar — but much further ranging — effect on the adoption and development of technologies that address prostate cancer?

Any such effect will barely hint at what is already happening on a much more expansive scale, the embrace of value medicine. Foreshadowed by isolated efforts at patient comfort and outcome, financial considerations have proven to be the determining factors for what is shaping up to be an overhaul of medical practice in this country and the technologies that serve it.

What we are seeing now and will see more of in the near future is testament to the extraordinary power of political forces. As the 21st century unfolds, it is very likely that political will, and the financial need to exercise it, will decide what the next generation of imaging scanners will do and when they will do it.

Editor’s note: This is the third blog in a series of four by industry consultant Greg Freiherr on Where Molecular Imaging Fits in Managing the Cancer Patient. To read the first blog, “How to Achieve the Quantitative Promise of PET/CT,” click here. To read the second blog, “Why the Use of PET/CT in Radiation Therapy Requires Thinking Outside the Box,” click here.

Related Content

Moffitt Cancer Center researchers are developing a noninvasive, accurate method to analyze a patient's tumor mutations and biomarkers to determine the best course of treatment.

Getty Images

News | Lung Imaging | October 19, 2020
October 19, 2020 — Personalized treatment options for patients with...
Indeterminate lesion on PET/CT classified by PET/MRI for 53-y-old man with lung cancer.

Indeterminate lesion on PET/CT classified by PET/MRI for 53-y-old man with lung cancer. Contrast-enhanced CT (A), PET (B), and fused 18F-FDG PET/CT (C) images are displayed in comparison with contrast-enhanced T1-weighted MRI (D), PET, and fused 18F-FDG PET/MRI (F) images. In CT (A), hyperdense, subcentimeter liver lesion (arrows) in segment VII is suggestive of transient hepatic attenuation difference or small hemangioma. As malignancy cannot be excluded, it needs further investigation. On PET/MRI, lesion is clearly classified as metastasis because of contrast enhancement and tracer uptake due to later acquisition time point. Follow-up CT confirmed diagnosis after 78 d. Images created by Ole Martin, University Dusseldorf, Medical Faculty and Benedikt Schaarschmidt, University Hospital Essen.

News | PET-MRI | September 18, 2020
September 18, 2020 — A single-center observational study of more than 1,000 oncological examinations has demonstrated
A 12-year-long collaboration with Canon Medical Research USA, Canon Medical Systems Japan and Southern Nevada outpatient radiology leader Steinberg Diagnostic Medical Imaging (SDMI) has resulted in the development of 3 PET scanners, each generation more advanced than the last
News | PET-CT | September 08, 2020
September 8, 2020 — A 12-year-long collaboration with...
a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology

a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Radiology Imaging | August 14, 2020
August 14, 2020 — According to ARRS' ...
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

News | PET-CT | July 16, 2020
July 16, 2020 — New research confirms the high impact of...
Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs

Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs using additional physiologically important parameters, for example, glucose transport rate K1 (d), across the entire body. Image courtesy of G.B. Wang, M. Parikh, L. Nardo, et al., University of California Davis, Calif.

News | PET Imaging | July 16, 2020
July 16, 2020 — Results from the first...
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020
July 15, 2020 — ...
Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

News | PET Imaging | July 15, 2020
July 15, 2020 — A first-in-human study presented at the Society of...
Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total

Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total-body PET/CT in osteoarthritis: affected joints include the left elbow, right knee (arrow) and right big toe (arrowhead). Image courtesy of YG Abdelhafez et al., University of California Davis, Sacramento, CA.

News | SNMMI | July 14, 2020
July 14, 2020 — For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneous